Swiss Pharma Industry Warns 100% US Tariffs Threaten Global Supply Chains

Switzerland's pharmaceutical association, Interpharma, has issued a stark warning regarding the potential impact of proposed 100% U.S. tariffs on the industry. The association stated that such aggressive trade measures would significantly threaten global production and disrupt critical supply chains. Major Swiss exporters, including industry giants Roche and Novartis, face substantial risks as the U.S. remains their largest market. Interpharma emphasized that these tariffs would ultimately lead to increased costs and harm patient health globally. The proposed policies by the Trump administration have sparked widespread concern across the healthcare sector and international trade bodies. Market analysts suggest that these developments could create significant headwinds for pharmaceutical stocks and the Swiss Franc.